ZLDPF Zealand Pharma A/S

Total number of shares and voting rights in Zealand Pharma at December 29, 2023

Total number of shares and voting rights in Zealand Pharma at December 29, 2023

Company announcement – No. 46 / 2023

Total number of shares and voting rights in Zealand Pharma at December 29, 2023

Copenhagen, Denmark, December 29, 2023 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. 

In Company announcement No. 43/2023 from December 7, 2023, Zealand announced an increase in share capital relating to exercise of employee warrants. Following these announcements, the table below lists the total number of shares and voting rights in Zealand up to and including December 29, 2023.



 



Date
Number of shares

(nominal value of DKK 1 each)
Share capital

(nominal value in DKK)
Number of voting rights
December 29, 202358,751,15258,751,15258,751,152

# # #

About Zealand Pharma A/S 

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit .

Contact:

Adam Lange

Investor Relations Officer

Zealand Pharma

Email:
 
Anna Krassowska, PhD

Vice President, Investor Relations & Corporate Communications

Zealand Pharma

Email:


EN
29/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE

Zealand Pharma increases its share capital as a result of the exercise...

Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 20 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 20,924 divided into 20,924 new shares ...

 PRESS RELEASE

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on...

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity. “Obesity is one of ...

 PRESS RELEASE

Zealand Pharma to participate in upcoming investor conferences in Sept...

Zealand Pharma to participate in upcoming investor conferences in September 2025 Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investo...

 PRESS RELEASE

Zealand Pharma major shareholder announcement: Van Herk Investments B....

Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Du...

Jacob Mekhael
  • Jacob Mekhael

Zealand Pharma 2Q25 results confirm timelines, upcoming CMD in Decembe...

Zealand's 2Q25 results hold no surprises, and show that the company is on track operationally with pipeline timelines being reiterated. While no big data readouts are expected for the remainder of the year, the company is gearing up for a news heavy 1H26 and we most look forward to phase 2b results with petrelintide (amylin analog, partnered with Roche). Zealand reported a cash position of DKK 16,578m, and expects an additional $ 250m in anniversary payments under the Roche agreement in addition...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch